Drug Trial Radar · NCT01640782
Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach
Last checked: Nov 19, 2026Latest source record: Jul 18, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,100
Actual
Start
Feb 2005
Primary completion
Jan 2013
Study completion Jan 2013
Sponsor
- Lead sponsor
- Mario Negri Institute for Pharmacological ResearchAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Aventis Pharmaceuticals; Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente; Gruppo Oncologico Italiano di Ricerca Clinica; Gruppo Oncologico del Nord-Ovest; Italian Trial in Medical Oncology; Southern Italy Cooperative Oncology Group; Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS; Oncotech
- First posted
- Jul 16, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Open label, randomised, multicenter, superiority study for efficacy. Patients with histologically proven adenocarcinoma of the stomach or gastroesophageal junction without gross or microscopic evidence of residual disease after surgery with curative intent and fulfilling all the inclusion/exclusion criteria are eligible for this study.
Conditions
- Adenocarcinoma of the Stomach
- Adenocarcinoma of the Gastroesophageal Junction
Interventions
Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, CisplatinDrug
* Irinotecan (CPT-11) 180 mg/m2, given as 60 min. i.v. infusion on day 1 every 2 weeks followed by * Leucovorin (LV) 100 mg/m2, given as a 2h i.v. infusion on days 1 and 2 every 2 weeks followed by * 5-Fluorouracil (5-FU) 400 mg/m2 given as bolus, and then 5-Fluorouracil (5-FU) 600 mg/m2 given as a 22h continuous infusion on days 1 and 2, every 2 weeks for 4 administrations. After 3 weeks from last infusion: * Docetaxel (TXT) 75 mg/m2, given as a 1h i.v. infusion on day 1 followed by * Cisplatin (CDDP) 75 mg/m2, given as a 1h i.v. infusion on.day 1, every 3 weeks, for 3 cycles.
Leucovorin, 5-FluorouracilDrug
* Leucovorin (LV) 100 mg/m2, given as a 2h i.v. infusion on days 1 and 2 every 2 weeks followed by * 5-Fluorouracil (5-FU) 400 mg/m2 given as bolus, and then 5-Fluorouracil (5-FU) 600 mg/m2 given as a 22h continuous infusion on days 1 and 2, every 2 weeks for 9 administrations.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival will be defined as the time from date of randomisation to date of first appearance of local, regional or distant relapse, or death from any cause; patients alive without relapse will be censored at date last known to be alive.Time frame: 3 years
Locations
101 sites in 1 country. Site status is shown where the registry gives one.
ASL 6 - Fabriano
Fabriano, Ancona, Italy
Ospedale Civile di Senigallia
Senigallia, Ancona, Italy
dell'Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I
Torrette Di Ancona, Ancona, Italy
Ospedale. S. Donato
Arezzo, Arezzo, Italy
Presidio Ospedaliero di Ariano Irpino
Ariano Irpino, Avellino, Italy
A.O. "G. Rummo"
Benevento, Benevento, Italy
Ospedali "Riuniti"
Bergamo, Bergamo, Italy
A.O. "Ospedale Treviglio-Caravaggio"
Treviglio, Bergamo, Italy
Ospedale degli Infermi di Biella
Biella, Biella, Italy
Ospedale Maggiore-Bellaria
Bologna, Bologna, Italy
A.O.Policlinico "S.Orsola-Malpighi"
Bologna, Bologna, Italy
Ospedale Sant'Orsola - Fatebenefratelli
Brescia, Brescia, Italy
Casa di Cura Poliambulanza di Brescia
Brescia, Brescia, Italy
Spedali Civili
Brescia, Brescia, Italy
P.O. di Monserrato - Policlinico Universitario di Cagliari
Monserrato, Cagliari, Italy
P.O. di Monserrato
Monserrato, Cagliari, Italy
P.O. Vittorio Emanuele
Catania, Catania, Italy
Ospedale Garibaldi in Nesima
Catania, Catania, Italy
A.O. Sant'Anna
Como, Como, Italy
Ospedale "Valduce"
Como, Como, Italy
Ospedale Civile "Ferrari"
Castrovillari, Cosenza, Italy
Presidio Ospedaliero di Lamezia Terme
Lamezia Terme, Cosenza, Italy
Ospedale "San Francesco" di Paola
Paola, Cosenza, Italy
A.O. "Ospedale Maggiore" di Crema
Crema, Crema, Italy
Azienda Ospedaliera "Istituti Ospitalieri" di Cremona
Cremona, Cremona, Italy
P.O. S. Lazzaro
Alba, Cuneo, Italy
A.O. "S.Croce e Carle"
Cuneo, Cuneo, Italy
Azienda Ospedaliera Universitaria "S.Anna"
Ferrara, Ferrara, Italy
Ospedale Santa Maria Annunziata
Antella, Firenze, Italy
Ospedale "San Giuseppe"
Empoli, Firenze, Italy
A.O. Universitaria Careggi
Florence, Firenze, Italy
A.O. "G.B.Morgagni-L.Pierantoni
Forlì, Forli, Italy
E.O. Ospedali Galliera di Genova
Genova, Genova, Italy
Istituto Nazionale per la Ricerca sul Cancro
Genova, Genova, Italy
P.O. "A.Manzoni" di Lecco
Lecco, Lecco, Italy
Azienda USL 6 - P.O. Livorno
Livorno, Livorno, Italy
Ospedale Civile di Casalpusterlengo
Lodi, Lodi, Italy
Ospedale "Campo di Marte"
Lucca, Lucca, Italy
A.O. "C.Poma"
Mantua, Mantova, Italy
Ospedale Civico di Carrara
Carrara, Massa Carrara, Italy
Showing 40 of 101 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.